ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Meloxicam

Also written as “HTX-011”, “N1539” and “Meloxicam tablet”.

Its studies are mostly in Pain, Postoperative · Osteoarthritis · Arthritis, Rheumatoid · Hernia, Inguinal · Pain, led by 16 companies.

Drug pageMeloxicam: every studyMany companies study it; this page follows only the 66 they lead. All 88 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Jul 4, 201466 company-led studies, 2 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Boehringer Ingelheim220 open or runningphase 4since Jul 4, 2014May 2, 2002none ahead
Heron Therapeuticsits history only161 open or runningphase 4since Oct 1, 2021Jun 9, 2015none ahead
Baudax Bioits history only70 open or runningphase 4since Mar 15, 2022Aug 31, 2015none ahead
Alkermesits history only30 open or runningphase 3since Sep 15, 2011Jul 23, 2009none ahead
Dr. Reddy's Laboratoriesits history only20 open or runningphase 1since Jul 12, 2010Jul 12, 2010none ahead
Eurofarma Laboratoriosits history only20 open or runningphase 3since Apr 24, 2012Apr 24, 2012none ahead
Grünenthalits history only20 open or runningphase 3since Sep 22, 2014Mar 18, 2013none ahead
Hikma Pharmaceuticalsits history only20 open or runningno phasesince Jan 15, 2008Jan 15, 2008none ahead
Teva Pharmaceutical Industriesits history only20 open or runningphase 1since Feb 6, 2009Feb 6, 2009none ahead
Viatrisits history only20 open or runningphase 1since Mar 30, 2008Mar 30, 2008none ahead

Also a collaborator on its studies: Eurotrials Brasil Consultores Cientificos Ltda.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Boehringer Ingelheim only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 2, 2002First study: phase 3 study in Arthritis, JuvenileFirst studyNCT00034853 · 180 enrolled · United States, Brazil, Mexico and more
  2. Jul 22, 2002Phase 3 study in Arthritis, RheumatoidNCT00042068 · 1,000 enrolled · United States, Argentina, Australia and more
  3. Oct 13, 20052 phase 3 studiesNCT00239395, NCT00239382
  4. Jan 19, 2006Phase 3 study in Arthritis, JuvenileNCT00279747 · 226 enrolled · Austria, Belgium, France and more
  5. Jul 1, 20149 phase 1 studies in HealthyNCT02180490, NCT02180477, NCT02181907 and 6 more
  6. Jul 4, 20142 phase 3 studiesNCT02183168, NCT02183064
  7. Jul 4, 20142 phase 4 studies in OsteoarthritisNCT02183129, NCT02183116
  8. Jul 4, 20142 phase 2 studiesNCT02183051, NCT02183025
  9. Aug 28, 2014Phase 4 study in PharyngitisNCT02229747 · 128 enrolled
  10. Sep 24, 2018Phase 1 study in HealthyNCT03684265 · 26 enrolled · Russian Federation

TargetBeta

PTGS2 →read by rule
“Cyclooxygenase-2 inhibitor”ChEMBL 37, by rule

Other programs on PTGS2

ProgramCompanyFurthest phaseStudies
AcetaminophenruleJohnson & Johnsonphase 4136
IbuprofenrulePfizerphase 4113
AspirinruleBayerphase 484
CelecoxibruleViatrisphase 478
EtoricoxibruleOrganonphase 435
dexketoprofenruleMenarini Groupphase 48
SulfasalazineruleBristol-Myers Squibbphase 47
dexibuprofenruleaponia-laboratories-incphase 46
BenzydamineruleAngelini Pharmaphase 44
DipyroneruleHypera Pharmaphase 44
PiroxicamruleTaisho Pharmaceuticalphase 44
FlurbiprofenruleGlaxoSmithKlinephase 312

Studies

All 22 Boehringer Ingelheim leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT03684265Healthy · Russian Federation1CompletedOct 30, 201826
NCT02229747Pharyngitis4CompletedFeb 2002128
NCT02187575Healthy1CompletedSep 200226
NCT02187562Healthy1CompletedAug 200216
NCT02183181Healthy1CompletedJan 20096
NCT02183168Spondylitis, Ankylosing3CompletedMay 1, 2002192
NCT02183129Osteoarthritis4CompletedNov 1, 199991
NCT02183116Osteoarthritis4CompletedFeb 199930
NCT02183077Healthy1CompletedNov 199812
NCT02183064Osteoarthritis3CompletedNov 20001,309
NCT02183051Pain2CompletedOct 1998381
NCT02183025Dysmenorrhea2CompletedApr 1999337
NCT02181907Healthy1CompletedApr 200322
NCT02181322Healthy1CompletedSep 200124
NCT02181309Healthy1CompletedApr 200224
NCT02180490Healthy1CompletedJul 200260
NCT02180477Healthy1CompletedDec 20019
NCT00279747Arthritis, Juvenile · Austria, Belgium, France and more3CompletedJan 2003226
NCT00239395Osteoarthritis · China3CompletedDec 2004168
NCT00239382Arthritis, Rheumatoid · China3CompletedDec 1, 2004150
NCT00042068Arthritis, Rheumatoid · United States, Argentina, Australia and more3Completed1,000
NCT00034853Arthritis, Juvenile · United States, Brazil, Mexico and more3CompletedJun 2003180

How it is read

Names in the registry

  • “HTX-011”, 20 entries
  • “N1539”, 18 entries
  • “Meloxicam”, 12 entries
  • “Meloxicam tablet”, 3 entries
  • “Meloxicam 15 mg Tablets”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.